Invivyd rises on plan to test measles antibody treatment

Invivyd

12/05/2025 13:00

** Shares of drugmaker Invivyd IVVD.O rise 11.4% to 72 cents premarket

** Co says it has started discovery program to test measles monoclonal antibody

** Monoclonal antibodies are lab-made proteins that mimic immune system's ability to fight off harmful pathogens such as viruses

     ** "Goal is to identify a preclinical monoclonal antibody candidate in 2025; anticipates providing a progress update by end of year," IVVD says

** There are currently no anti-viral treatments for measles; measles vaccine is 97% effective after two doses, according to CDC

** Measles cases in U.S. crossed 1,000 for first time in five years, federal data showed on May 9

** Up to last close, stock up 45.8% YTD

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com))